Клинический случай ремиссии без лечения хронического миелолейкоза

15. Ernst T., Erben P., Muller M.C., Paschka P., Schenk T., Kre S., Rosee P.L., Hehlmann R., Hochhaus A. Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib. Haematologica. 2008; 93 (2): 186-192. doi: 10.3324/haematol.11993.

16. Garcia-Gonzales Р., Laing R., David T. The survival of patients enrolled in a global direct-to-patient cancer medicine donation program: The Glivec International Patient Assistance Program (GIPAP). EClinicalMedicine. 2020; 19:100257. doi: 10.1016/j.eclinm.2020.100257.

17. Gunz F. W. The epidemiology and genetics of the chronic leukaemias. Clinics in Haematology. 1977; 6 (1): 3-20.

18. Kanavos Р., Vandoros S., Garcia-Gonzales P. Benefits of global partnerships to facilitate access to medicines in developing countries: a multicountry analisis of patients and patient outcomes in GIPAP. Globalization and health. 2009; 5: 19. doi: 10.1186/1744-8603-5-19.

19. Mahon F. X., Nicolini F. E., Noel M. P. Preliminary report of the STIM2 study: a multicentre stop imatinib trial for chronic phase chronic myeloid leukemia de novo patients on imatinib. The Lancet. Oncology. 2010; 11: 1029-1035. doi: 10.1016/S1470-2045(10)70233-3.

20. Marin D., Milojkovic D., Olavarria E., Khorashad J. S., de Lavallade H., Reid A. G., Foroni L., Rezvani K., Bua F. Dazzi M., Pavlu J., Klammer M. European Leukemia Net criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood. 2008; 112 (12): 4437-4444. doi: 10.1182/blood-2008-06-162388.

21. Decree of the Government of the Russian Federation of October 17, 2007 No. 682 Moscow “On the centralized purchase in 2008 and 2009 of medicines intended for the treatment of patients with hemophilia, cystic fibrosis, pituitary nanism, Gaucher disease, myeloid leukemia, multiple sclerosis, as well as after organ and (or) tissue transplantation”. URL : https://rg.ru/2007/10/19/lekarstva-zakupka-dok.html. (In Russ.).

22. Order of the Ministry of Health and Social Development of the Russian Federation of November 14, 2007 No. 704 “On approval of the standard of medical care for patients with myeloid leukemia and other hemoblastoses.” URL : https://www.medkirov.ru/docs/id/2F4250/$File/704_14112007.pdf. (in Russ.).

23. Kutsev S., Oxenjuk O., Ovsyannikova E., Turkina A High imatinib plasma level is critically important for complete cytogenetic response maintenance in CML patients. Haematologica the hematology journal. - 16^th congress of the European Hematology Association (London, Abstract book). 2011; 96 (2): 289-290.

24. Ovsyannikova E. G., Israpilova Z. M., Zakljakova L. V., Popov E. A. Allelic polymorphism of the HLA- DRB1 gene in chronic myeloid leukemia. Fundamental'nye issledovaniya = Fundamental research. 2011; 10 (chast' 3): 538-541. (in Russ.).

25. Ovsyannikova E. G., Popov E. A., Davydkin I. L., Levitan B. N., Zaklyakova L. V., Shcherbak L. A., T eplyi A. D. Modern aspects of diagnosis, prognosis and treatment of chronic myeloid leukemia. Astrakhanskiy meditsinskiy zhurnal = Astrakhan Medical Journal. 2015; 10 (3): 27-44. (in Russ.).

26. Ovsyannikova E. G., Davydkin I. L., Popov E. A., Israpilova Z. M, Zaklyakova L. V. Association of Gene HLA-DRB1 Polymorphism with the Outcome of Therapy of Chronic Myeloid Leukemia with Imatinib. Haematologica the hematology journal. - 18^th Congress of the European Hematology Association (Sweden, Stockholm. Abstract book). 2013; 98: 563.

27. Abdulkadyrov K. M., Abdullaev A. O., Avdeeva L. B., Afanas'ev B. V., Vinogradova E. Ju., Vinogradova O. Ju., Volkova S. A., Glonina N. N., Glyzhina E. V., Golenkov A. K., Gusarova G. A., Domracheva E. V., Dubov S. K., Zakljakova L. V., Zarickij A. Ju., Ivanova V. L., Krinicyna E. E., Kuznecov S. V., Kuz'mina L. A., Kucev S. I, Kuchma G. B., Lazareva O. V., Lomaia E. G., Martynkevich I. S., Matveeva L. F., Morozova E. V., Peljaeva V. M., Rusakov M. N., Sudarikov A. B., Turkina A. G., Fominyh M. S., Horoshko N. D., Caur G. A., Chelysheva N. Ju., Shuvaev V. A., Shuhov O. A. Federal clinical guidelines for the diagnosis and therapy of chronic myeloid leukemia .Vestnik gematologii = Bulletin of Hematology. 2013; 9 (3): 4-42. (in Russ.).

28. Kutsev S. I., Shatokhin Yu. V. The effect of interruptions of imatinib therapy on the achievement of cytogenetic and molecular responses in patients with chronic myeloid leukemia. Kazanskiy meditsinskiy zhurnal = Kazan Medical Journal. 2009; 90 (6): 827-831. (in Russ.).

29. Zaritskiy A. Yu., Lomaya E. G., Vinogradova O. Yu., Druzhkova G. A., Kruglov S. S. The results of a multicenter study of glivec therapy in patients with chronic myeloid leukemia in the chronic phase. Gematologiya i transfuziologiya = Hematology and transfusiology. 2007; 52 (2): 13-17. (in Russ.).

30. Turkina A. G., Zaritskiy A. Yu., Shuvaev V. A., Chelysheva E. Yu., Lomaia E. G., Morozova E. V., Golenkov A. K., Pospelova T. I., Shukhov O. A., Fominykh M. S., Gusarova G. A., Kuz'mina L. A., Abdullaev A. O., Martynkevich I. S. Clinical recommendations for the diagnosis and treatment of chronic myeloid leukemia. Klinicheskaya onkogematologiya = Clinical oncohematology. 2017; 10 (3): 294-316. (in Russ.).

31. Charles M., Bollu V., Hornyak E., Coombs J., Blanchette C. M. Predictors of treatmetnt non-adherence in patients treated with imatinib mesilate for chronic myeloid leukemia. Blood. 2009; 114 (22): 2209.

32. Saussele S., Richter J., Guilhot J., Gruber F. X., Hjorth-Hansen H., Almeida A., Janssen J. J. W. M., Mayer J., Koskenvesa P., Panayiotidis P., Olsson-Stromberg U., Martinez-Lopez J., Rousselot P., Vestergaard H., Ehrencrona H., Kairisto V., Fabarius A., Hofmann W.K., Hochhaus A., Pfirrmann M., Mahon F.X. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. The Lancet Oncology. 2018; 19 (6): 747-757.doi: 10.1016/S1470- 2045(18)30192-X.

33. Campiotti L. Imatinib discontinuation in chronic myeloid leukaemia patients with undetectable BCR-ABL transcript level: A systematic review and a meta-analysis. European Journal of Cancer. Elsevier Ltd. 2017; 77: 48- 56.doi: 10.1016/j.ejca.2017.02.028.

34. Dulucq S., Mahon F. Deep molecular responses for treatment-free remission in chronic myeloid leukemia. Cancer medicine. 2016; 5 (9): 2398-411.

35. Hughes T.P., Moiraghi B., Mahon F., Boquimpani C., Kim Dong-Wook, Benyamini N., Clementino N., Shuvaev V., Ailawadhi S., Lipton J., Turkina A., de Paz R., Moiraghi B., Nicolini F. Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a SingleGroup, Phase 2, Open-Label Study. Ann Intern. 2018; 168 (7): 461-470. doi: 10.7326/M17-1094.

36. Lee S. E., Choi S., Bang J-h., Kim, Eun-Jung Jang, Ji-Young Byeun, Kim S-H., Park J. E., Jeon H. R., Oh Y. J., Kim H. J., Kim Y. K., Park J. S., Jeong S., Kim S. H., Zang D., Oh S., Kim H., Do Y., Kwak J., Kim J. A., Kim D. Y., Mun Y., Mauro M., Kim D. W. Kyeoung Predictive factors for successful imatinib cessation in chronic myeloid leukemia patients treated with imatinib. American journal of hematology. 2013; 88 (6): 449-454.

37. Mahon F. X., Rea D., Guilhot J., Guilhot F., Huguet F., Nicolini F., Legros L., Charbonnier A., Guerci A., Varet B., Etienne G., Reiffers J., Rousselot P. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. The Lancet Oncology. 2010; 11 (11): 1029-1035. doi: 10.1016/S1470-2045(10)70233-3.

38. Pfirmann M., Mahon F., Guilhot J., Richter J., Almeida A., Janssen J. No differences in molecular relapse-free survival after stopping imatinib treatment of chronic myeloid leukemia between patients with prior 4.5 log reduction (MR4.5) but detectable and patients with undetectable disease in the EURO-SKI trial = Blood. 2016; 128 (22): abstract 789.

39. Richter J., Mahon F. X., Guilhot J., Hjorth - Hansen H., Almeida A., Janssen J., Mayer J., Porkka K., Panay- iotidis P., Olsson-Str U. Stopping tyrosine kinase inhibitors in a very large cohort of European chronic myeloid leukemia patients: results of the EURO-SKI trial. Haematologica. 2016; 101: 145.

40. Saglio G., Gale R. Prospects for achieving treatment-free remission in chronic myeloid leukaemia. British journal of haematology. 2020; 190 (3): 318-327. doi: 10.nn/bjh.16506.

41. Afanas'ev B. V., Abdullaev A. O., Al'-Radi L. S., Vinogradova O. Yu., Golenkov A. K., Zaritskiy A. Yu., Kuz'mina L. A, Kutsev S. I., Lomaia E. G., Martynkevich I. S., Morozova E. V., Obukhova T. N., Pospelova T. I., Su- darikov A. B., Turkina A. G., Tsaur G. A., Fominykh M. S., Chelysheva E. Yu., Shuvaev V. A., Shukhov O. A. Chronic myeloid leukemia, age group adults: clinical recommendations. 2020; 87 p. (in Russ.).

42. Turkina A. G., Chelysheva E. Yu., Shuvaev V. A., Gusarova G. A., Bykova A. V., Shukhov O. A., Petrova A. N., Vakhrushev M. V., Goryacheva S. R., Kolosova L. Yu., Krasikova P. S., Fominykh M. S., Martynkevich I. S., Abdullaev A. O., Sudarikov A. B., Savchenko V. G. Results of observation of patients with chronic myeloid leukemia with a deep molecular response without therapy with tyrosine kinase inhibitors. Terapevticheskij arhiv = Therapeutic archive. 2017; 89 (12):1286-1296. doi: 10.17116/terarkh2017891286-96. (in Russ.).

43. Chelysheva E. Yu. New principles of therapy of patients with chronic myeloid leukemia. Thesis of Doctor of Medical Sciences. Moscow; 2021. 277p. (in Russ.).

44. Chelysheva E., Petrova A., Shukhov O. First interim analysis of the Russian multicenter prospective study

ruski: discontinuation of tyrosine kinase inhibitors in patients with chronic myeloid leukemia and deepmolecular response. 23^th Congress of European Hematology Association. Hematologica. 2018; 2 (1):374. doi:

10.1016/j.clml.2019.12.019.

45. Petrova А., Chelysheva E., Shukhov O., Bykova А., Nemchenko I., Gusarova G., Tsyba N., Julakian U., Shuvaev V., Fominykh M., Martynkevich I., Ionova T., Turkina А. Withdrawal syndrome after tyrosine kinase inhibitors discontinuation inpatients with chronic myeloid leukemia and deep molecular response in a multicenter prospective study (RU-SKI). HemaSphere. 2019; 3: 876-877.

46. Abdulkadyrov K. M., Shuvaev V. A., Chechetkin A. V., Bessmel'tsev S. S., Martynkevich I. S. Diagnosis and treatment of chronic myeloid leukemia with pharmacological justification : metodicheskie rekomendacii = methodological recommendations. Saint Petersburg: RosNIIGT FMBA. 2016; 25 p. (in Russ.).

47. Ovsyannikova E. G., Kaplanov K. D., Klitochenko T. Yu., Misyurin A. V., Davydkin I. L., Zaklyakova L. V., Popov E. A., Levitan B. N. Mutational status of imatinib-resistant patients with chronic myeloid leukemia. Onko- gematologiya = Oncohematology. 2012; 7: 16-24. (in Russ.).

48. Petrova A. N., Ionova T. I., Chelysheva E. Yu., Zinkovskaya A. V., Bykova A. V., Krasikova P. S., Nemchenko I. S., Nikitina T. P., Porfir'eva N. M., Shukhov A. O., Tsyba N. N., Turkina A. G. Assessment of the quality of life in patients with chronic myeloid leukemia with a deep molecular response after discontinuation of therapy with tyrosine kinase inhibitors : results of preliminary analysis. Vestnik mezhnatsional'nogo tsentra issledovaniya kachestva zhizni = Bulletin of the International Center for Quality of Life Research. 2018; (4). :31 -32. (in Russ.).

49. Hochhaus M., Baccarani R. T., Silver C., Cortes J. E., Deininger M. W., Guilhot F., Hjorth-Hansen H., Hughes T. P., Janssen J. J. W. M., Kantarjian H. M., Kim D. W., Larson R. A., Lipton J. H., Mahon F. X., Mayer J., Nicolini F., Niederwieser D., Pane F., Radich J. P., Rea D., J. Richter, Rosti G., Rousselot P., Rousselot P., Saglio G., Sauhele S., Soverini S., Steegmann J. L., Turkina A., Zaritskey A., Hehlmann R. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020; 34 (4): 966-984. doi: 10.1038/s41375-020-0776-2.

Размещено на Allbest.ru